$5.85
6.36% yesterday
Nasdaq, May 20, 10:03 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$5.85
+1.06 22.13% 1M
-2.20 27.33% 6M
-1.36 18.86% YTD
-2.19 27.24% 1Y
+0.83 16.53% 3Y
-0.21 3.47% 5Y
-231.45 97.53% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.35 6.36%
ISIN
US02155H1014
Symbol
ALT
Sector
Industry

Key metrics

Market capitalization $474.48m
Enterprise Value $326.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16,310.00
P/S ratio (TTM) P/S ratio 23,724.00
P/B ratio (TTM) P/B ratio 3.20
Revenue growth (TTM) Revenue growth -95.12%
Revenue (TTM) Revenue $20.00k
EBIT (operating result TTM) EBIT $-98.19m
Free Cash Flow (TTM) Free Cash Flow $-80.33m
Cash position $149.87m
EPS (TTM) EPS $-1.25
P/E forward negative
P/S forward 151,833.60
EV/Sales forward 104,384.00
Short interest 29.55%
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Altimmune, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Altimmune, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.02 0.02
95% 95%
100%
- Direct Costs 0.16 0.16
-
800%
-0.14 -0.14
-
-700%
- Selling and Administrative Expenses 21 21
26% 26%
106,800%
- Research and Development Expense 77 77
9% 9%
382,700%
-98 -98
12% 12%
-490,150%
- Depreciation and Amortization 0.16 0.16
-
800%
EBIT (Operating Income) EBIT -98 -98
11% 11%
-490,965%
Net Profit -90 -90
3% 3%
-451,200%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pem...
Neutral
GlobeNewsWire
7 days ago
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
Neutral
Seeking Alpha
7 days ago
Altimmune, Inc. (NASDAQ:ALT ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayk...
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website www.altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today